Bristol-Myers Squibb Company Ce
CELG-RI - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$194.06M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $194.06 Million |
|---|---|
| Enterprise Value | $10.50 Billion |
| Earnings per Share | $3.47 |
| Beta | -0.47 |
| Outstanding Shares | 2,043,000,000 |
Return
| Return on Equity | 76.47% |
|---|---|
| Return on Assets | 22.35% |
| Return on Invested Capital | 28.15% |
Valuation & Multiples
| P/E Ratio | 0.02 |
|---|---|
| PEG | -1.18 |
| Price to Sales | 0.0 |
| Price to Book Ratio | 0.02 |
| Enterprise Value to Revenue | 0.21 |
| Enterprise Value to EBIT | 1.03 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 1.9 |
| Debt to Equity | 1.65 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 29, 2026
EPS Estimate
$1.72
Consensus analyst estimateRevenue Estimate
$12.59 B
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 0.01% |
|---|---|
| Total Invested | $16▼ 99.94% |
| Investors Holding | 1▼ 13.00% |
About Bristol-Myers Squibb Company Ce
34,100 employees
CEO: Christopher S. Boerner
Bristol Myers Squibb Company (BMS) operates as a biopharmaceutical enterprise, managing the entire lifecycle of its therapeutic products, from initial discovery and development to manufacturing, marketing, and distribution. Its diverse p...